Insights from the German Compassionate Use Program of Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis

Background: Nintedanib is approved for the treatment of idiopathic pulmonary fibrosis (IPF) and has been shown to slow disease progression by reducing annual lung function decline. Objective: To evaluate the results of a large cohort of IPF patients treated with nintedanib within a compassionate use...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Respiration 2016-01, Vol.92 (2), p.98-106
Hauptverfasser:	Bonella, Francesco, Kreuter, Michael, Hagmeyer, Lars, Neurohr, Claus, Keller, Claus, Kohlhaeufl, Martin J., Müller-Quernheim, Joachim, Milger, Katrin, Prasse, Antje
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Antineoplastic Agents - therapeutic use Clinical Investigations Compassionate Use Trials Drug therapy Female Germany Humans Idiopathic Pulmonary Fibrosis - drug therapy Indoles - therapeutic use Male Medication Adherence Nintedanib Patient outcomes Pulmonary fibrosis Retrospective Studies Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!